drug_type
RELEVANT_DRUG
intervention_type
Biological — Cellular therapy (CAR T cells)
drug_description
Autologous T lymphocytes genetically modified to express a PSCA-targeted chimeric antigen receptor with 4-1BB co-stimulation and CD3ζ signaling, including a truncated CD19 tag for selection/tracking; administered intravenously after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes engineered to express a PSCA-specific chimeric antigen receptor (scFv-4-1BB-CD3zeta). CAR binding to PSCA on tumor cells delivers CD3zeta activation and 4-1BB co-stimulation, promoting T-cell proliferation, cytokine release, and perforin/granzyme-mediated killing of PSCA-positive cells. A truncated CD19 tag enables selection/tracking; given after lymphodepletion to support CAR-T expansion.
drug_name
Autologous Anti-PSCA CAR T cells (Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes)
nct_id_drug_ref
NCT05805371